We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+0.51%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.57B
AUM Growth
-$21.5M
Cap. Flow
+$32.3M
Cap. Flow %
1.25%
Top 10 Hldgs %
39.02%
Holding
197
New
37
Increased
49
Reduced
41
Closed
10

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$39M
2
JNJ icon
Johnson & Johnson
JNJ
+$21.2M
3
ESPR
Esperion Therapeutics
ESPR
+$13.9M
4
ABBV icon
AbbVie
ABBV
+$11.5M
5
BMY icon
Bristol-Myers Squibb
BMY
+$11.4M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$36.3M
2
AMGN icon
Amgen
AMGN
+$29.7M
3
BIIB icon
Biogen
BIIB
+$20.8M
4
ALXN
Alexion Pharmaceuticals
ALXN
+$19.2M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$17.9M

Sector Composition

Rank Sector Weight
1 Healthcare 93.47%
2 Real Estate 2.71%
3 Financials 0.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GILD icon
1
Gilead Sciences
GILD
$163B
$156M 6.05%
2,063,699
-456,582
-18% -$36.3M
CELG
2
DELISTED
Celgene Corp
CELG
$121M 4.69%
1,352,842
-161,062
-11% -$15.5M
AMGN icon
3
Amgen
AMGN
$209B
$119M 4.65%
700,588
-161,586
-19% -$29.7M
JNJ icon
4
Johnson & Johnson
JNJ
$617B
$114M 4.45%
893,082
+156,950
+21% +$21.2M
BIIB icon
5
Biogen
BIIB
$30.7B
$104M 4.03%
378,703
-66,904
-15% -$20.8M
VRTX icon
6
Vertex Pharmaceuticals
VRTX
$122B
$100M 3.89%
614,084
-29,678
-5% -$4.85M
UNH icon
7
UnitedHealth
UNH
$383B
$75.4M 2.93%
352,317
+46,431
+15% +$10.6M
PFE icon
8
Pfizer
PFE
$142B
$72.8M 2.83%
2,162,748
+1,135,006
+110% +$39M
VTRS icon
9
Viatris
VTRS
$20.7B
$71.1M 2.77%
1,726,967
+123,855
+8% +$5.28M
MRK icon
10
Merck
MRK
$321B
$69.9M 2.72%
1,345,655
-40,005
-3% -$2.16M
ILMN icon
11
Illumina
ILMN
$31B
$69.7M 2.71%
303,149
+9,356
+3% +$2.14M
ALXN
12
DELISTED
Alexion Pharmaceuticals
ALXN
$55.6M 2.16%
498,975
-160,643
-24% -$19.2M
INCY icon
13
Incyte
INCY
$24.9B
$53.8M 2.09%
645,442
-47,833
-7% -$4.31M
REGN icon
14
Regeneron Pharmaceuticals
REGN
$77.4B
$48.1M 1.87%
139,560
-30,956
-18% -$10.8M
ABT icon
15
Abbott
ABT
$183B
$47.9M 1.86%
798,619
– –
ABBV icon
16
AbbVie
ABBV
$455B
$42.7M 1.66%
450,738
+104,425
+30% +$11.5M
MDT icon
17
Medtronic
MDT
$110B
$41.9M 1.63%
522,211
+16,185
+3% +$1.33M
AGN
18
DELISTED
Allergan plc
AGN
$41.9M 1.63%
248,836
+40,656
+20% +$6.82M
LLY icon
19
Eli Lilly
LLY
$1.03T
$37.7M 1.47%
486,865
+103,766
+27% +$8.35M
BMY icon
20
Bristol-Myers Squibb
BMY
$132B
$33.3M 1.29%
525,722
+176,601
+51% +$11.4M
HUM icon
21
Humana
HUM
$44B
$31.9M 1.24%
118,733
-19,823
-14% -$5.37M
TMO icon
22
Thermo Fisher Scientific
TMO
$214B
$30.5M 1.19%
147,855
+9,887
+7% +$2.08M
IDXX icon
23
Idexx Laboratories
IDXX
$44.1B
$29.3M 1.14%
153,076
+20,724
+16% +$3.82M
NVS icon
24
Novartis
NVS
$301B
$28.4M 1.1%
391,738
-34,442
-8% -$2.62M
SRPT icon
25
Sarepta Therapeutics
SRPT
$1.64B
$28M 1.09%
378,516
+44,116
+13% +$2.94M
1
2 3 4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q1 2018 Portfolio in Review

As of Q1 2018, Tekla Capital Management held 197 positions worth $2.57B, down 0.83% from $2.59B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Tekla Capital Management's Q1 2018 filing shows 37 new, 49 increased, 41 reduced and 10 closed positions. Its largest new stake was Esperion Therapeutics: 189,287 shares worth $13.7M. The largest sale was Gilead Sciences, an estimated $36.3M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 93% a quarter earlier, followed by Real Estate and Financials.

  • Tekla Capital Management's largest Q1 2018 buy was Esperion Therapeutics: 189,287 shares worth $13.7M.
  • Tekla Capital Management added most to Pfizer in Q1 2018, an estimated $39M increase.
  • Tekla Capital Management's biggest Q1 2018 reduction was Gilead Sciences, cutting an estimated $36.3M.
  • Tekla Capital Management fully exited NuVasive, Inc. in Q1 2018, selling an estimated $6.87M.
  • Tekla Capital Management's ten largest holdings make up 39% of its $2.57B portfolio in Q1 2018.
  • Tekla Capital Management opened 37 new positions and closed 10 in Q1 2018.
  • Tekla Capital Management's portfolio value fell 0.83% quarter-over-quarter to $2.57B.

Based on Tekla Capital Management's 13F filing for Q1 2018, filed 14 May 2018.